NCT01832506View on ClinicalTrials.gov

A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

October 31, 2014

Conditions
Solid Tumors
Interventions
DRUG

MSC2156119J

Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.

Trial Locations (2)

Unknown

Research site, Kashiwa

Research site, Shizuoka

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01832506 - A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter